These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12121967)

  • 1. Hematologic effects of linezolid: summary of clinical experience.
    Gerson SL; Kaplan SL; Bruss JB; Le V; Arellano FM; Hafkin B; Kuter DJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2723-6. PubMed ID: 12121967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid.
    Kuter DJ; Tillotson GS
    Pharmacotherapy; 2001 Aug; 21(8):1010-3. PubMed ID: 11718489
    [No Abstract]   [Full Text] [Related]  

  • 3. Hematologic effects of linezolid in young children.
    Meissner HC; Townsend T; Wenman W; Kaplan SL; Morfin MR; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S186-92. PubMed ID: 14520145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure.
    Mateu de Antonio J; Grau S; Morales-Molina JA; Marín-Casino M
    Clin Infect Dis; 2006 May; 42(10):1500; author reply 1501. PubMed ID: 16619168
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.
    Tsuji Y; Hiraki Y; Matsumoto K; Mizoguchi A; Kobayashi T; Sadoh S; Morita K; Kamimura H; Karube Y
    J Infect Chemother; 2011 Feb; 17(1):70-5. PubMed ID: 20582446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid and reversible myelosuppression.
    Arellano FM
    JAMA; 2001 Oct 24-31; 286(16):1973-4; discussion 1974. PubMed ID: 11667930
    [No Abstract]   [Full Text] [Related]  

  • 7. Linezolid-Induced anemia and thrombocytopenia.
    Waldrep TW; Skiest DJ
    Pharmacotherapy; 2002 Jan; 22(1):109-12. PubMed ID: 11794421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center.
    Minson Q; Gentry CA
    Pharmacotherapy; 2010 Sep; 30(9):895-903. PubMed ID: 20795845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.
    Hiraki Y; Tsuji Y; Matsumoto K; Morita K; Kamimura H; Karube Y
    Am J Med Sci; 2011 Dec; 342(6):456-60. PubMed ID: 21681075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid and reversible myelosuppression.
    Green SL; Maddox JC; Huttenbach ED
    JAMA; 2001 Mar; 285(10):1291. PubMed ID: 11255382
    [No Abstract]   [Full Text] [Related]  

  • 11. Linezolid and reversible myelosuppression.
    Lawyer MC; Lawyer EZ
    JAMA; 2001 Oct 24-31; 286(16):1974. PubMed ID: 11667931
    [No Abstract]   [Full Text] [Related]  

  • 12. Linezolid and reversible myelosuppression.
    Abena PA; Mathieux VG; Scheiff JM; Michaux LM; Vandercam BC
    JAMA; 2001 Oct 24-31; 286(16):1973; author reply 1974. PubMed ID: 11667929
    [No Abstract]   [Full Text] [Related]  

  • 13. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
    Wu VC; Wang YT; Wang CY; Tsai IJ; Wu KD; Hwang JJ; Hsueh PR
    Clin Infect Dis; 2006 Jan; 42(1):66-72. PubMed ID: 16323094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia associated with linezolid therapy.
    Attassi K; Hershberger E; Alam R; Zervos MJ
    Clin Infect Dis; 2002 Mar; 34(5):695-8. PubMed ID: 11803505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of linezolid.
    French G
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii45-53. PubMed ID: 12730142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections.
    Rao N; Ziran BH; Wagener MM; Santa ER; Yu VL
    Clin Infect Dis; 2004 Apr; 38(8):1058-64. PubMed ID: 15095207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.
    Plachouras D; Giannitsioti E; Athanassia S; Kontopidou F; Papadopoulos A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2006 Nov; 43(9):e89-91. PubMed ID: 17029128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid-associated thrombocytopenia.
    Lam S
    Consult Pharm; 2012 Jul; 27(7):504-8. PubMed ID: 22910131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic effects of linezolid versus vancomycin.
    Young LS
    Clin Infect Dis; 2004 Apr; 38(8):1065-6. PubMed ID: 15095208
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.
    Soriano A; Ortega M; García S; Peñarroja G; Bové A; Marcos M; Martínez JC; Martínez JA; Mensa J
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2559-63. PubMed ID: 17470658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.